pha-408 and Dermatitis

Psoriasis is a chronic inflammatory autoimmune disease that can be initiated by excessive activation of endosomal toll-like receptors (TLRs), particularly TLR7, TLR8, and TLR9. Therefore, inhibitors of endosomal TLR activation are being investigated for their ability to treat this disease. The currently approved biological drugs adalimumab, etanercept, infliximab, ustekinumab, ixekizumab, and secukizumab are antibodies against effector cytokines that participate in the initiation and development of psoriasis. Several immune modulatory oligonucleotides and small molecular weight compounds, including IMO-3100, IMO-8400, and CPG-52364, that block the interaction between endosomal TLRs and their ligands are under clinical investigation for their effectiveness in the treatment of psoriasis. In addition, several chemical compounds, including AS-2444697, PF-05387252, PF-05388169, PF-06650833, ML120B, and PHA-408, can inhibit TLR signaling. Although these compounds have demonstrated anti-inflammatory activity in animal models, their therapeutic potential for the treatment of psoriasis has not yet been tested. Recent studies demonstrated that natural compounds derived from plants, fungi, and bacteria, including mustard seed,

Topics: Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Curcumin; Cytokines; Dermatitis; Endosomes; Humans; Imiquimod; Indazoles; Isonicotinic Acids; Mice; Psoriasis; Resveratrol; Signal Transduction; Skin; Stilbenes; Toll-Like Receptor 7; Toll-Like Receptor 8; Toll-Like Receptor 9; Toll-Like Receptors